Elanco Animal Health (ELAN) to Release Quarterly Earnings on Tuesday

Elanco Animal Health (NYSE:ELAN) is expected to issue its quarterly earnings data before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of $0.16 per share and revenue of $1.01 billion for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Elanco Animal Health Trading Down 1.0 %

NYSE:ELAN opened at $11.02 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The firm has a 50-day moving average of $11.80 and a 200-day moving average of $13.10. The company has a market cap of $5.45 billion, a PE ratio of 27.54, a PEG ratio of 2.50 and a beta of 1.42. Elanco Animal Health has a one year low of $10.77 and a one year high of $18.80.

Analyst Upgrades and Downgrades

ELAN has been the subject of several recent research reports. Stifel Nicolaus decreased their target price on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Friday. UBS Group assumed coverage on shares of Elanco Animal Health in a research report on Monday, December 9th. They set a “buy” rating and a $18.00 target price for the company. Leerink Partners assumed coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective for the company. Leerink Partnrs raised shares of Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Finally, Morgan Stanley reduced their price objective on shares of Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 29th. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $16.00.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.